Back to today’s briefing

Story perspectives

Breakthrough Trial Achieves 100% Survival in Breast Cancer

5/14/2025

43 4

Summary

Story summary

A groundbreaking clinical trial at Addenbrooke's Hospital in Cambridge has revealed that combining Olaparib, a targeted drug, with chemotherapy can lead to a remarkable 100% survival rate after three years for patients with early-stage breast cancer and BRCA mutations. This promising outcome could revolutionize treatment for those battling aggressive inherited cancers.

1 of 1

Story summary

A groundbreaking clinical trial at Addenbrooke's Hospital in Cambridge has revealed that combining Olaparib, a targeted drug, with chemotherapy can lead to a remarkable 100% survival rate after three years for patients with early-stage breast cancer and BRCA mutations. This promising outcome could revolutionize treatment for those battling aggressive inherited cancers.